Archive · 2 Jun 2025
Piramal Pharma Shares Rise After USFDA Inspection
Imagine a company called Piramal Pharma that makes medicine.
A government agency called the USFDA checks to make sure their factories are doing things the right way.
The USFDA checked Piramal Pharma's factory in Canada and found everything was perfect, like a good report card.
This made investors happy, and the company's stock price went up a bit.
The company's profits and sales have also been increasing.
Even though there are some worries about money for new biotech ideas, the company is still doing well overall and expects to reach its goals.
Piramal Pharma's shares increased after a positive USFDA inspection.
The inspection took place at the Aurora, Canada facility.
The USFDA issued a form 483 with zero observations.
The company's fourth-quarter profit increased by 51.5%.
Piramal Pharma is working towards its 2030 revenue and margin targets.
- Who
- Piramal Pharma Ltd.
- What
- USFDA issued a form 483 with zero observations at the Aurora facility in Canada.
- When
- Shares gained on Monday, June 2, after inspection.
- Where
- Aurora, Canada
- Why
- To meet its 2030 revenue and margin targets and due to positive inspection results.
Uncertainties
Positive Outlook
Biotech Funding
Uncertainties
Early-stage biotech funding remains uneven.
Positive Outlook
Demand for late-stage clinical development services continues to hold up well.
- USFDA Inspection
- Zero observations, no action indicated (NAI) for Aurora, Canada facility
- Facility Location
- Aurora, Canada
- Inspection Dates
- May 26 to May 30
- Q4 Net Profit Increase
- 51.5% to ₹153.5 crore
- Revenue Increase
- 7.9% to ₹2,754 crore
- EBITDA Increase
- 5.9% to ₹561 crore
- EBITDA Margin
- 20.45%
- Share Price Increase
- 1.5% on June 2